LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lakewood-Amedex Biotherapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.58+0.00 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $828.29K
- P/E (TTM)
- –
- Dividend yield
- –
About Lakewood-Amedex Biotherapeutics
Pharmaceutical Preparations, SIC 2834
Lakewood-Amedex Biotherapeutics Inc. is listed on Nasdaq under the ticker LABT, in the SEC industry Pharmaceutical Preparations. It is incorporated in Nevada and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Lakewood-Amedex Biotherapeutics Inc.
- Headquarters
- University Park, FL
- Address
- 8031 Cooper Creek Blvd., Suite 103 34201
- Phone
- (941) 225-2515
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- LABT
- Exchange
- Nasdaq
- IPO date
- Apr 23, 2026
- Shares outstanding
- 2M, Aug 3, 2026
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jun 22, 2026
- SEC CIK
- 2079272
- CUSIP
- 51255A201
- ISIN
- US51255A2015
- EIN
- 20-5274304
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kelvin Cooper | Chief Executive Officer, Director | 300,594 |
| Thomas Balzer | Chief Medical Officer | 255,322 |
| Peter Ceccacci | Chief Financial Officer | 468,148 |
| Joseph Edward Tucker | Director | 0 |
| Leonard James DeRoma | Director | 187,736 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 23, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 17, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |